Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
NEW YORK Drug maker Pfizer said Sunday it would immediately stop advertising its best-selling arthritis pain reliever Celebrex to consumers after a study showed high doses of it were associated with an increased heart attack risk.
New York-based Pfizer spent more than $70 million advertising Celebrex to U.S. consumers in the first nine months of this year.
Publicis Groupe’s Kaplan Thaler Group here handles ads for the brand. The agency’s first work for Celebrex broke in October.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in